SOPHiA GENETICS Raises $30 Million in Series D Funding to Accelerate its Mission of Democratizing Data-Driven Medicine Worldwide
Wednesday, September 13, 2017
LAUSANNE, Switzerland, September 13, 2017 /PRNewswire/ --
SOPHiA GENETICS, the global leader in Data-Driven Medicine that has created SOPHiA
Artificial Intelligence, today announced the close of a $30 million Series D funding
round. The round was led by London-based Balderton Capital joined by 360 Capital Partners
alongside existing investors British tech star Mike Lynch's Invoke Capital and Alychlo,
the investment firm of Belgian pharmaceutical entrepreneur Marc Coucke.
(Logo: http://mma.prnewswire.com/media/555440/SOPHiA_GENETICS_Logo.jpg )
The company's universal technology, SOPHiA AI, accurately analyzes and detects all
types of genomic variants to help clinicians better diagnose and treat their patients. Its
innovative technology and global approach were recently recognized by the MIT Technology
Review's "50 Smartest Companies"
[https://www.technologyreview.com/lists/companies/2017/#sophia-genetics ] , who ranked
SOPHiA GENETICS thirtieth. SOPHiA is being used daily by 334 hospitals across 53 countries,
and has tested over 125,000 patients to date.
This new round of funding enables SOPHiA GENETICS to continue its journey of
democratizing Data-Driven Medicine worldwide. The company will use these resources to
further develop its cutting-edge technology. Additionally, the company will continue
recruiting top talent and accelerate hospitals' adoption of clinical genomics testing, no
matter if they are equipped (with a Next-Generation DNA Sequencing lab) or not. The
company's dedicated team who develops SOPHiA is driven to support clinicians by providing
them with the best diagnosis technologies and helping them to find treatment options that
"Since inception, our vision has been to develop innovative technological solutions to
help patients, equally wherever they live. SOPHiA acts as a real disruptor by breaking
down the information silos in healthcare, meaning that the information from a patient in
London or Paris can for instance help better diagnose and treat a patient in Lagos or Rio,
" - Dr. Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS.
This is only the beginning. With more and more hospitals adopting SOPHiA AI, the
company has created the largest clinical genomics community which enables the hundreds of
institutions in the network to safely and anonymously share their findings and knowledge
while ensuring patient data privacy.
"While recent technology disruptions have made DNA sequencing more affordable and
available to the masses, issuing a clinically-proofed diagnostic based on a large set of
genomic data remained time consuming and largely incomplete for healthcare professionals.
Clinicians using SOPHiA GENETICS' artificial intelligence now have a best-in-class
technology to unlock the full knowledge hidden behind DNA samples, and to set the right
diagnostic for the right condition, in particular for oncology and hereditary disorders.
The clinicians we met were unanimous about the incredible value brought by SOPHiA as part
of their daily routine. We have been very impressed by the accomplishments of the team to
date, and we are very excited to be working alongside the founders towards establishing
SOPHiA GENETICS as the global leader in Data-Driven Medicine (DDM), " - Nicolas Autret,
Partner at 360degree(s) Capital Partners.
In the near future, each medical interaction will start with a genomic test
corroborated with other patients' health records. This 'Real Time Epidemiology' is paving
the way for the new era of efficient personalized medicine and SOPHiA is at the forefront
of facilitating this deployment.
"SOPHiA GENETICS is a company at the forefront of two rapidly changing
technologies: genomic medicine and artificial intelligence. By giving every healthcare
professional a standardized, straightforward and fast way to analyze these complex data
sets is an essential step to unlock the potential of Data-Driven Medicine. As diagnostic
kits and sequencers become cheaper and more powerful, we believe that there is
an opportunity to build the defining software layer on top of these technologies
in genomics, just as Windows did for PCs and Android has for smartphones, and
SOPHiA GENETICS is already leading in this field," - James Wise, Partner at Balderton
Global leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company which
has developed SOPHiA AI, the most advanced technology for clinical genomics, helping
healthcare professionals better diagnose and treat patients. The global network of 334
institutions from 53 countries that use the SOPHiA DDM(R) analytical platform powered by
SOPHiA form the world's largest clinical genomics community. By enabling the rapid
adoption of genomic testing worldwide, turning data into actionable clinical insights, and
sharing knowledge through its community, SOPHiA GENETICS is democratizing Data-Driven
Medicine to save lives. More info: http://www.sophiagenetics.com.
SOPHiA GENETICS is on Twitter, follow @SOPHiAGENETICS
Balderton Capital: is one of the largest venture capital firms in Europe, focused on
investing in the best European technology companies at Series A. Based in London, the firm
manages $2.3bn. Since 2000, Balderton has invested in over 100 companies, principally
Notable investments include Talend (open-source data integration provider, went public
on Nasdaq in 2016); Magic Pony Technologies (acquired by Twitter in 2016); NaturalMotion
(the mobile gaming developer, sold to Zynga in 2014); Betfair (the online betting exchange,
2010 IPO; LOVEFiLM (the home entertainment subscription service, sold to Amazon in 2011);
MySQL, (the open-source database software, sold to Sun Microsystems in 2008); and YOOX
Group (the online retailer of leading fashion brands, IPO in 2009). The current portfolio
includes companies such as 3D Hubs, Citymapper, Kobalt Music, Prodigy Finance, Qubit,
Scytl, ROLI, Talend, and The Hut Group. More info: http://www.balderton.com.
360degree(s)Capital Partners is a Venture Capital firm, investing in Innovation at
full scale, in Europe and more particularly in France and Italy.
Over Euro 300m under management in the last 15 years, 360degree(s) Capital Partners is
managed by a consolidated team which has cumulated 60+ years of Venture Capital experience
in investing in, following-up and/or exiting from over 80 companies. They leverage an
important international network, having co-invested with major international Venture
Capital funds in over 10 countries with a proven top quartile track record, either as
individuals or as a team, in very different economic environments. More info:
SOURCE SOPHiA GENETICS
||Global Power Transformers Industry | Nov 17, 2017
||Airflow Management Market Worth 807.3 Million USD by 2023 | Nov 17, 2017
||Global Lighting as a Service Market, Analysis and Forecast Report 2017 - Key Players are Philips, GE, Acuity Brands Lighting, Sparkfund, Enlighted and Zumtobel | Nov 17, 2017
||Stocks Under Scanner in the Medical Equipment Space -- ResMed, Smith & Nephew, Stryker, and Zimmer Biomet | Nov 17, 2017
||Where Voices Are Heard and Talent is Cast | Nov 17, 2017
||Chikpea Inc. Announced Stephen Deason Is Joining The Force.com Agile Subscriber Relationship Management Solutions Team As The New Chief Financial And Operating Officer, Effective November 1, 2017 | Nov 17, 2017
||Achain Partners with Tsinghua's iCenter, Delivering a Fresh Breeze to Blockchain Education | Nov 17, 2017
||Global Smart Augmented Reality (AR) Glasses Industry | Nov 17, 2017
||Proxyclick, Next Generation Visitor Management Specialist, closes £2.7million Series A Funding | Nov 17, 2017
||Pre-Market Technical Recap on Electronics Stocks -- LG Display, Control4, Corning, and TE Connectivity | Nov 17, 2017